Aventis and Watson Reach Settlement on Litigation
Advertisement
Aventis Pharma AG, the pharmaceutical company of Aventis, announced today that it has settled litigation with Watson Pharmaceuticals Inc. related to the hypertension drug Dilacor® XR (dilatizem).
Terms of the settlement were not material to the financial position of Aventis, which previously had recorded reserves for potential liability in connection with the dispute.
The settlement relates to a lawsuit filed by Watson in a U.S. District Court in California in August 1999 against Rhone Poulenc Rorer Inc., a predecessor company of Aventis. The lawsuit alleged breach of a manufacturing and supply agreement and a non-compete clause contained in a 1997 license agreement granting certain rights to Dilacor XR® to Watson.
Most read news
Other news from the department science
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Trinseo Europe GmbH - Horgen, Switzerland
HAMILTON opened Representative office in Shanghai
Coherent_(company)
ACTEGA Rhenacoat S.A. - Sedan, France
Rotating molecules create a brighter future
Tiny particles could help verify goods
WILHELM BAHMÜLLER Maschinenbau Präzisionswerkzeuge GmbH - Plüderhausen, Germany
BASF increases prices for polyetheramines
Materials processing tricks enable engineers to create new laser material
FACCTs GmbH - Köln, Germany